Advisory Board
Paul Aisen, MD
PROFESSOR, USC
Paul Aisen, MD is Professor of Neurology at USC; Director, Alzheimer’s Therapeutic Research Institute; Co-Director, Clinical Core for the Alzheimer’s Disease Neuroimaging Initiative; and a member of the Alzheimer’s Clinical Trials Consortium Leadership Team. Dr. Aisen is a highly respected clinician who has led many Alzheimer’s disease clinical trials.
Roger Armen, PhD
PROFESSOR, THOMAS JEFFERSON UNIVERSITY
Roger Armen, PhD is an Assistant Professor of Pharmaceutical Sciences at the Medical School of Thomas Jefferson University. He is an expert in medicinal chemistry and computational drug design. Dr. Armen is Co-discoverer of the α-sheet structure in the Daggett Research Group.
Ronald DeMattos, PhD
SVP and CSO for NEUROBIOLOGICALS, ELI LILLY and COMPANY
Ronald B. DeMattos, Ph.D. is a Senior Vice President and Chief Scientific Officer for Neurobiologics at Lilly. Dr. DeMattos received his doctorate in molecular and cellular biochemistry (SUNY – Stony Brook, 1998) and performed a post-doctoral fellowship at Washington University School of Medicine (Holtzman Lab). Dr. DeMattos joined Eli Lilly in 2002 and he has subsequently held multiple scientific positions within Neuroscience Discovery over the last 20+ years. Dr. DeMattos discovered/developed numerous compounds for clinical studies in Alzheimer’s disease patients including Donanemab (positive Phase-3) and Remturnetug (Phase-3 ongoing), Lilly’s plaque lowering antibodies. He currently leads the Indianapolis Neurodegeneration group comprised of talented scientists and staff whose mission is to develop novel first-in class therapies for neurodegeneration and Alzheimer’s disease indications.
Sir Alan Fersht, PhD
PROFESSOR, CAMBRIDGE UNIVERSITY
Sir Alan Fersht, PhD is a Professor at Cambridge University and the Medical Research Council. He has co-founded 3 biotech companies including Cambridge Antibody Technology. Dr. Fersht serves on the Scientific Advisory Boards of HFS Research and others.
Samuel Gandy, MD, PhD
PROFESSOR, MOUNT SINAI
Sam Gandy, MD, PhD is Professor of Neurology and Psychiatry at Mount Sinai; Associate Director of the Mount Sinai Alzheimer’s Disease Research Center; and Past Chairman of the National Medical and Scientific Advisory Council of the Alzheimer’s Association. Dr. Gandy is a clinician and scientific expert in the cell biology and toxicity of fibrillar and oligomeric forms of the amyloid beta peptide (Aβ).
Charles Glabe, PhD
PROFESSOR, UC IRVINE
Charles Glabe, PhD is Professor of Molecular Biology and Biochemistry at University of California, Irvine. Dr. Glabe is an expert in the structure and aggregation of amyloid proteins, particularly Aβ, and was the first to synthesize and characterize Aβ. Dr. Glabe developed the widely used A11 antibody and made the seminal discovery that amyloidogenic toxic oligomers contain a common structure and common mechanism of pathogenesis.
Steven E. Kahn, MB, ChB
PROFESSOR, UNIVERSITY of WASHINGTON
Steven E. Kahn, MB, ChB, is a Professor of Medicine at the University of Washington (UW), Director of the UW Diabetes Research Center and is also a clinician at the VA Puget Sound Health Care System. An expert in Type 2 diabetes, Dr. Kahn continues to participate in some of the major NIH clinical studies examining the pathophysiology, prevention and treatment of Type 2 diabetes.
Michael Levitt , PhD
PROFESSOR, STANFORD UNIVERSITY
Michael Levitt, PhD pioneered the field of protein modeling and multiscale computational approaches, for which he was co-recipient of the 2013 Nobel Prize in Chemistry. He serves on the Scientific Advisory Boards of Affymetrix, Amgen, Cocrystal Pharma, Dupont Merck Pharmaceuticals and others.
Jeff Roh, MD, MBA, MSc
CEO, INTUITIVEX
Jeff Roh, MD, MBA, MSc serves as the Director of Minimally Invasive Spine Surgery at the Swedish Neuroscience Institute and Chairman of Swedish Hospital’s Integrated Spine Program. He has more than 15 years of experience as an inventor, angel investor, and serial entrepreneur and holds multiple patents.